Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
GlaxoSmithKline Oy
OY
Active
Y-tunnus 0108378-4
Porkkalankatu 20A, 00180
Helsinki
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 1970 · 55 years old
86 employees
Share
Finland
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
GlaxoSmithKline Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
100M
75M
50M
25M
0M
2021: 69M
69M
2021
2022: 78M (+13% vs 2021)
78M
+13%
2022
2023: 80M (+3% vs 2022)
80M
+3%
2023
2024: 78M (-2% vs 2023)
78M
-2%
2024
2025: 78M (0% vs 2024)
78M
0%
2025
EBITDA
EUR millions
5M
4M
2M
1M
0M
2021: 3M
3M
2021
2022: 3M (0% vs 2021)
3M
0%
2022
2023: 4M (+33% vs 2022)
4M
+33%
2023
2024: 3M (-25% vs 2023)
3M
-25%
2024
2025: 3M (0% vs 2024)
3M
0%
2025
Income statement
EUR thousands
Item
2025
2024
2023
2022
2021
Revenue
77 617
78 090
79 804
77 647
68 561
Staff expenses
−0
−0
−0
−22 216
−21 728
EBITDA
2 587
2 735
3 634
3 015
2 988
Depreciation & amort.
−0
−0
−0
−490
−684
EBIT
2 587
2 735
3 634
2 525
2 304
Net financials
1
268
182
−17
−23
Profit before tax
2 588
3 003
3 816
2 508
2 281
Tax
479
624
780
567
521
Net profit
2 109
2 378
3 036
1 941
1 760
Balance sheet
EUR thousands
Item
2025
2024
2023
2022
2021
Total assets
21 783
23 763
21 924
25 157
27 880
Equity
9 369
9 560
10 181
9 046
8 804
Long-term debt
0
0
0
—
—
Short-term debt
12 414
14 203
11 742
16 112
19 077
Total debt
12 414
14 203
11 742
16 112
19 077
Financial ratios
5-year trend
EBITDA margin
3,3 %
This company
15,8 %
Market median
This company
Market median
79% below market
2021
2025
Equity ratio
43,0 %
This company
38,2 %
Market median
This company
Market median
13% above market
2021
2025
Return on equity
22,5 %
This company
18,4 %
Market median
This company
Market median
22% above market
2021
2025
Net profit margin
2,7 %
This company
8,1 %
Market median
This company
Market median
67% below market
2021
2025
Asset turnover
3,56×
This company
1,12×
Market median
This company
Market median
218% above market
2021
2025
Debt / equity
1,33×
This company
0,62×
Market median
This company
Market median
115% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
More on GlaxoSmithKline Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
